| Primary information |
|---|
| ID | antitb_1446 |
| Peptide Name | A2-ESAT |
| Sequence | LLDEGKQSL |
| N-terminal Modification | Free |
| C-terminal Modification | Free |
| Chemical Modification | None |
| Linear/ Cyclic | Linear |
| Length | 9 |
| Chirality | L |
| Nature | NA |
| Source | Protein derived |
| Origin | MTB derived protein ESAT6 |
| Species | Mycobacterium tuberculosis |
| Strain | Mycobacterium tuberculosis Rv |
| Inhibition Concentartion | NA |
| In vitro/In vivo | NA |
| Cell Line | NA |
| Inhibition Concentartion | NA |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Response | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment |
| Mechanism of Action | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. |
| Target | CD8+ T-cell |
| Combination Therapy | NA |
| Other Activities | NA |
| Pubmed ID | 25809751 |
| Year of Publication | 2104 |
| 3-D Structure |  View in Jmol or Download Structure |